Last Updated: 02/12/2024
Malaria Vaccine Adjuvant Immunogenicity and Safety
Objectives
The objective of these studies is to provide a better understanding of cellular and molecular correlates of immunogenic efficacy and safety of nanoparticle formulations, and also provide the basis for more in-depth studies on vaccine development, in general.
Specific objectives:
- We propose to develop Pfs25 – nanoparticle formulations
- Evaluate functional immune response in inbred and outbred mice
- We also propose to study the immune response-related host gene expression changes at the site of vaccine injection to gain mechanistic insights of Pfs25-nanoparticle vaccine efficacy.
- Finally studies are also proposed to investigate relevant vaccine safety parameters
Principal Institution
Principal Investigators / Focal Persons
Rationale and Abstract
In Plasmodium falciparum, Pfs230 and Pfs48/45 proteins produced within the intra-erythrocytic gametocyte stages and Pfs25, expressed during the mosquito stage development of zygote into ookinete, represent well-established target antigens of transmission-blocking antibodies.
Project Outputs
External reference
Date
Aug 2012 — Jun 2014
Total Project Funding
$414,868
Funding Details
National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), United States
Project number: 5R21AI101427
Project Site
Deep Dives
Related Resources
